{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:31:59Z","timestamp":1793914319573,"version":"4.8.0"},"reference-count":34,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"unspecified","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Medical Research Special Project for Shanghai Science and Technology Innovation Action Plan","award":["24Y12800400"],"award-info":[{"award-number":["24Y12800400"]}]},{"name":"Shanghai Henlius Biotech"},{"name":"the National Natural Science Foundation of People\u2019s Republic of China","award":["82430099 and 82573547"],"award-info":[{"award-number":["82430099 and 82573547"]}]},{"name":"Burning Rock Biotech"},{"name":"the Clinical Research Special Project of Shanghai Municipal Health Commission","award":["202440070"],"award-info":[{"award-number":["202440070"]}]},{"name":"the National Key R&D Program of China","award":["2022YFA1103900"],"award-info":[{"award-number":["2022YFA1103900"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,26]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Squamous non-small cell lung cancer (sq-NSCLC) is a distinct subtype of NSCLC. This exploratory, phase II study investigated the feasibility and efficacy of a four-cycle perioperative regimen combining serplulimab with a taxane (paclitaxel or nab-paclitaxel) and carboplatin in patients with resectable stage II-IIIA sq-NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This investigator-initiated, single-arm, phase II exploratory trial (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05775796\">NCT05775796<\/jats:ext-link>\n                      ) enrolled patients with histologically confirmed, resectable clinical stage II-IIIA squamous NSCLC. Patients received two to three cycles of neoadjuvant serplulimab plus taxane-carboplatin, followed by curative-intent surgery and one to two cycles of adjuvant treatment. The primary endpoint was major pathological response (MPR). Secondary endpoints included pathological complete response (pCR), R0 resection rate, overall response rate (ORR), safety, event-free survival (EFS), and overall survival (OS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 30 patients without actionable driver alterations were enrolled and 29 underwent surgery. The median age was 65 years, and most were male smokers (n=28, 93.33%). Surgery was performed in 29 patients, and R0 resection was achieved in 96.55% (28\/29) of the surgically resected patients. Among all enrolled patients, MPR and pCR rates were 76.67% and 50.00%, respectively. Based on radiological assessments during the neoadjuvant phase, the ORR was 73.33% (95% CI 54.11% to 87.72%). Grade \u22653 treatment-related adverse events were predominantly hematologic and were generally manageable. Long-term EFS and OS data are not yet mature. Additionally, exploratory minimal residual disease analysis using circulating tumor DNA (ctDNA) in 27 patients showed a strong correlation between ctDNA clearance and pCR (p=0.004), suggesting ctDNA as a promising biomarker for immunochemotherapy response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A four-cycle perioperative regimen of serplulimab combined with taxane-carboplatin demonstrated promising MPR and pCR rates with an acceptable safety profile in patients with resectable sq-NSCLC. Long-term follow-up and future phase III trials are warranted to confirm these exploratory findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05775796\">NCT05775796<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014437","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:55:25Z","timestamp":1778504125000},"page":"e014437","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05775796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05775796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05775796","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fangqiu","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqiang","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongze","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xusheng","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-721X","authenticated-orcid":false,"given":"Yaodong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-0601","authenticated-orcid":false,"given":"Yihua","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengping","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[{"name":"Burning Rock Biotech, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[{"name":"Burning Rock Biotech, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7846-257X","authenticated-orcid":false,"given":"Haiquan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Institute of Thoracic Oncology, Fudan University, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2026051105552093000_14.5.e014437.1","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"2026051105552093000_14.5.e014437.2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jtho.2017.11.111","article-title":"Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer","volume":"13","author":"Socinski","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2026051105552093000_14.5.e014437.3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ccell.2023.12.004","article-title":"A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"2026051105552093000_14.5.e014437.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01990"},{"key":"2026051105552093000_14.5.e014437.5","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31824a9022"},{"key":"2026051105552093000_14.5.e014437.6","article-title":"Adjuvant chemotherapy for resected early-stage non-small cell lung cancer","volume":"2015","author":"Burdett","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026051105552093000_14.5.e014437.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9030"},{"key":"2026051105552093000_14.5.e014437.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"2026051105552093000_14.5.e014437.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01756-2"},{"key":"2026051105552093000_14.5.e014437.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.16464"},{"key":"2026051105552093000_14.5.e014437.11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2005.01.001","article-title":"Complete resection in lung cancer surgery: proposed definition","volume":"49","author":"Rami-Porta","year":"2005","journal-title":"Lung Cancer (Auckl)"},{"key":"2026051105552093000_14.5.e014437.12","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","article-title":"Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"key":"2026051105552093000_14.5.e014437.13","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102334","article-title":"ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep Med"},{"key":"2026051105552093000_14.5.e014437.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70334-6"},{"key":"2026051105552093000_14.5.e014437.15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8010","article-title":"Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816","volume":"42","author":"Spicer","year":"2024","journal-title":"JCO"},{"key":"2026051105552093000_14.5.e014437.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304875"},{"key":"2026051105552093000_14.5.e014437.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302983"},{"key":"2026051105552093000_14.5.e014437.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311926"},{"key":"2026051105552093000_14.5.e014437.19","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318247504a"},{"key":"2026051105552093000_14.5.e014437.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.116","article-title":"1243P Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): Systematic literature review and meta-analysis","volume":"31","author":"Waser","year":"2020","journal-title":"Ann Oncol"},{"key":"2026051105552093000_14.5.e014437.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405220101"},{"key":"2026051105552093000_14.5.e014437.22","doi-asserted-by":"crossref","DOI":"10.5334\/aogh.2419","article-title":"Global Epidemiology of Lung Cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann Glob Health"},{"key":"2026051105552093000_14.5.e014437.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050753"},{"key":"2026051105552093000_14.5.e014437.24","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S1470-2045(20)30475-7","article-title":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","volume":"21","author":"Redman","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026051105552093000_14.5.e014437.25","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2147\/OTT.S125397","article-title":"EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?","volume":"10","author":"Joshi","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2026051105552093000_14.5.e014437.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001"},{"key":"2026051105552093000_14.5.e014437.27","first-page":"774","article-title":"Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer","volume":"12","author":"Chen","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"2026051105552093000_14.5.e014437.28","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/jnci\/djae137","article-title":"Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis","volume":"116","author":"Chu","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026051105552093000_14.5.e014437.29","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03844-w","article-title":"Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis","volume":"73","author":"Han","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026051105552093000_14.5.e014437.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30453-8"},{"key":"2026051105552093000_14.5.e014437.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24735"},{"key":"2026051105552093000_14.5.e014437.32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026051105552093000_14.5.e014437.33","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jtho.2024.07.002","article-title":"Clinical Utility of Tumor-Na\u00efve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC","volume":"19","author":"Hong","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026051105552093000_14.5.e014437.34","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jtho.2024.06.024","article-title":"Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC","volume":"19","author":"Jun","year":"2024","journal-title":"J Thorac Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:55:28Z","timestamp":1778504128000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,11]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2025-014437"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014437","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}